Pyxis Oncology(PYXS)
BOSTON, MABiotechnology
Focus: Pyxis Oncology is a public-stage biotechnology company focused on antibody immunotherapy for solid tumors and hematologic malignancies. The company operates with minimal revenue ($16M) while maintaining a high R&D spend, indicating a pipeline-driven model.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Pyxis Oncology?
AI assessmentPyxis offers high-risk, high-reward science exposure for early-career researchers willing to bet on immunotherapy validation and successful financing, but cash runway and hiring freeze suggest near-term instability.
Why Work Here
- Early-stage pipeline with 5 clinical programs across oncology, offering exposure to antibody immunotherapy drug development at the Phase 1-2 level
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$16M
Pipeline & Clinical Trials
PYX-201
Solid TumorClinical Trials (1)
NCT05720117A Study of PYX-201 in Advanced Solid Tumors
Phase 1Help build intelligence for Pyxis Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.